ImmPACT Bio USA emerged from the FutuRx incubator in Israel in 2017 to develop chimeric antigen receptor T-cell (CAR-T) therapies that could be effective against solid tumors. Now, with $111m in series B venture capital announced on 20 January, ImmPACT aims to build out its three separate technology platforms that are designed to solve multiple first-generation CAR-T problems.
ImmPACT Raises $110m As Bispecific CAR-T Shows Promising Response Rates
Next-Gen Cell Therapy Firm Aims To Solve First-Gen Problems
ImmPACT Bio is advancing three CAR-T technology platforms that aim to address problems such as antigen escape, off-target toxicities and the immunosuppressive tumor microenvironment.
More from Financing
More from Business
• By
Public Company Edition: Stock valuations are falling due to political, economic and regulatory uncertainty, resulting in fewer large public offerings, more alternative financings and cost cuts. Carisma, Tenaya, BioAtla, Arbutus, Nkarta, Alector and Adaptimmune announced layoffs.
• By
The US FDA approved anti-CD19 antibody Uplizna, from Amgen’s $27.8bn purchase of Horizon in 2023, for IgG4-related disease – a larger market than its original NMOSD indication.
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.